Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes.

ABSTRACT:

Objective

Metabolic activation of the innate immune system governed by interleukin (IL)-1β contributes to β-cell failure in type 2 diabetes. Gevokizumab is a novel, human-engineered monoclonal anti-IL-1β antibody. We evaluated the safety and biological activity of gevokizumab in patients with type 2 diabetes.

Research design and methods

In a placebo-controlled, dose-escalation study, a total of 98 patients were randomly assigned to placebo (17 subjects) or gevokizumab (81 subjects) at increasing doses and dosing schedules. The primary objective of the study was to evaluate the safety profile of gevokizumab in type 2 diabetes. The secondary objectives were to assess pharmacokinetics for different dose levels, routes of administration, and regimens and to assess biological act

SUBMITTER: Cavelti-Weder C 

PROVIDER: S-EPMC3402269 | biostudies-literature | 2012 Aug

REPOSITORIES: biostudies-literature